Comparative Pharmacology
Head-to-head clinical analysis: DECABID versus VISTARIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DECABID versus VISTARIL.
DECABID vs VISTARIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Decabid is a combination of chlorpheniramine (antihistamine) and pseudoephedrine (decongestant). Chlorpheniramine competitively antagonizes histamine at H1 receptors, reducing allergic symptoms. Pseudoephedrine acts as a sympathomimetic agent, stimulating alpha-adrenergic receptors to cause vasoconstriction, reducing nasal congestion.
Hydroxyzine is a piperazine derivative antihistamine that acts as a competitive antagonist of histamine H1 receptors, thereby suppressing histamine activity in the subcortical area of the central nervous system. It also has anxiolytic, sedative, antiemetic, and antispasmodic effects.
1 capsule orally every 12 hours; each capsule contains 10 mg phenylephrine hydrochloride and 75 mg carbinoxamine maleate.
Oral: 50-100 mg 4 times daily; IM: 25-100 mg every 4-6 hours as needed.
None Documented
None Documented
12 hours (terminal); prolonged to 24 hours in renal impairment (CrCl <30 mL/min)
Terminal elimination half-life: 20-25 hours in adults; prolonged in hepatic impairment or elderly; steady-state achieved in ~4-5 days.
Renal (50% as unchanged drug), fecal (40% as metabolites), biliary (10% as glucuronide conjugates)
Primarily hepatic metabolism; <1% excreted unchanged in urine; biliary/fecal elimination of metabolites accounts for approximately 50-60% of total clearance.
Category C
Category C
Antihistamine/Decongestant Combination
Antihistamine